Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 21, 1997

View Archived Issues

Isis Pharmaceuticals: HY 1997 highlights

The Immune Response Corporation: HY 1997 highlights

Aurora Biosciences licenses fluorescent technology from the University of California

NIH researcher outlines ups and downs of malaria vaccine research

CombiChem/Athena initiate CNS drug discovery collaboration

Ginkgo biloba extract stabilizes dementia in patients in U.S. trial

CoCensys receives NIH grant to develop caspase inhibitors

Further indications of divalproex efficacy in dementia

Yale-Vion developing bacteria-based cancer treatment

New formulation of diazepam launched in U.S.

First launch for Yamanouchi bisphosphonate

Megestrol + ibuprofen for cancer cachexia

Potential new anticancer vaccines described

Dexanabinol: pharmacokinetics in humans

P&G agrees to outlicense antiarrhythmic drug

CPC-111 reduces pain of sickle cell crises in phase II

Selective suppression of Th1 cytokine production with TAK-603

RTP Pharma and Elan create company dedicated to ciclosporin development

Pharmacyclics enters into licensing agreement with Nycomed for Lu-Tex

First new narcolepsy therapy in decades cleared in U.K.

Celgene reports phase I/II trial results of d-methylphenidate for ADHD

Novartis granted option for TP-10 in xeno/allotransplants; preliminary results in lung transplant

Positive results obtained with Theratechnologies' AIDS gene therapy

Gensia receives FDA approval for desmopressin acetate injection

Bexxar compared to unlabeled MAb in patients with non-Hodgkin's lymphoma

Update on development of NeoPharm's novel chimeric human protein

Matritech files for clearance of new colon cancer test with FDA

Atlantic's sulfated cyclodextrins effective in preclinical models of restenosis

Taisho, Abbott to collaborate on macrolide antibacterials

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for April 21, 2026
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
Psychedelic space expanding on Trump’s EO
BioWorld
Timothy Leary is dead, but he could be on the outside looking in with a smile on his face as U.S. President Donald Trump’s latest executive order (EO) fuels a...
At AACR: Epigenetic fingerprints in metastases track tumor origin
BioWorld
When a tumor migrates and colonizes another tissue or organ, it can be identified as a metastasis, but its origin is not always clear. Now, a study based on...